Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.79 |
| ▸ | IGF1R | P08069 | 4/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.65 |
| ▸ | SYK | P43405 | 1/20 | 0.64 |
| ▸ | RHOA | P61586 | 1/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.61 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.61 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | GSK3A | P49840 | 2/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262378 | 0.88 | GSK3B (1.00) | GSK3BIGF1RMAPK8SYKCHEK1 | |
| SCHEMBL6701811 | 0.87 | GSK3B (0.64) | GSK3BIGF1RMAPK8SYKRHOA | |
| SCHEMBL12518611 | 0.85 | EGFR (0.76) | GSK3BSYKRHOAAURKAGSK3A | |
| SCHEMBL4459525 | 0.84 | IGF1R (1.00) | GSK3BIGF1RMAPK8SYKCHEK1 | |
| SCHEMBL3275303 | 0.83 | SYK (0.92) | GSK3BIGF1RMAPK8SYKCDK19 | |
| SCHEMBL656685 | 0.82 | AURKA (0.79) | GSK3BIGF1RMAPK8SYKNTRK2 | |
| Trifluoroacetic Acid SCHEMBL6674348 | 0.81 | GSK3B (0.71) | GSK3BIGF1RMAPK8SYKCHEK1 | |
| SCHEMBL13648626 | 0.81 | GSK3B (0.53) | GSK3BIGF1RMAPK8SYKRHOA | |
| SCHEMBL655512 | 0.80 | IGF1R (0.75) | GSK3BIGF1RMAPK8SYKCDK19 | |
| Hydrochloric Acid SCHEMBL6676130 | 0.79 | GSK3B (0.72) | GSK3BIGF1RMAPK8SYKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| CN-1211373-C | 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | disclosed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| CN-1406230-A | 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-03-26 | — | — | CN | disclosed |
| EP-1268444-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001064655-A1 | 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | GSK3B 455/4885IGF1R 789/4885MAPK8 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.